IMRT

2019 – SIOG – NBTXR3 for the treatment of elderly/frail HNSCC patients

New therapeutic approaches are needed for elderly or frail head and neck squamous cell carcinoma (HNSCC) patients (pts) ineligible for standard of care. NBTXR3, hafnium oxide nanoparticles injected intratumorally, may represent an option. Otherwise inert, NBTXR3 augments the radiation therapy (RT) dose within tumor cells when activated by RT, increasing tumor cell death compared to RT alone. […]

Continue Reading...

2019 – ASTRO – NBTXR3 for the treatment of solid tumors

Local interventional treatments of cancers include interventional radiology and radiotherapy (RT). NBTXR3, hafnium oxide nanoparticles, is deeply associated to both. Given as a single local administration it increases energy dose deposit inside tumor cells only when activated by ionizing radiation. Various interventional treatments have been used to treat cancers such as liver, lung, bone. Because entirely new therapies such as NBTXR3 are being introduced, implementation of interventional approaches is continuously growing. […]

Continue Reading...

2019 – ASCO – Phase I NBTXR3 in elderly/frail HNSCC patients

New therapeutic approaches are needed for elderly or frail head and neck squamous cell carcinoma (HNSCC) patients (pts) ineligible for standard of care treatment. NBTXR3, a crystalline solution of hafnium oxide nanoparticles may represent such an option. Injected intratumorally, NBTXR3 enters tumor cells and yields an increased cell-localized energy deposit upon exposure to radiotherapy (RT), leading to increased tumor cell death compared to the same dose of RT alone. […]

Continue Reading...

2019 – ICHNO – Phase I/II NBTXR3 in HNSCC

Hafnium oxide nanoparticles, NBTXR3, were developed to augment tumor-localized high energy deposit once activated by ionizing radiation such as Intensity Modulated Radiation Therapy (IMRT) and thus to increase tumor cell death compared to the same dose of radiation. NBTXR3 is characterized by a single intratumoral (IT) administration and fits into standard radiotherapy schedule with no change in patient’s care pathway, treatment protocol or equipment. […]

Continue Reading...

2018 – ESTRO – Hafnium Oxide Nanoparticles and Radiotherapy: A Promising New Treatment Strategy

With recent advances in radiation delivery techniques, an increasing number of cancer patients undergo radiotherapy. However, due to the non-targeted nature of radiotherapy, doses are limited by potential toxicity to surrounding normal tissue. Thus, a major challenge remains to develop new strategies to improve the tumor selectivity of radiation therapy. […]

Continue Reading...

By continuing to use the site, you agree to the use of cookies.En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies. More information.En savoir plus.

The cookie settings on this website are set to “allow cookies” to give you the possibility to switch between languages in a way that this will not interfere with page navigation. If you continue to use this website without changing your cookie settings or you click “Accept” below then you are consenting to this.Par défaut, les paramètres de ce site autorisent les cookies pour vous permettre notamment de naviguer entre les différentes langues disponibles. Nous utilisons des cookies pour vous proposer un site internet facile d'utilisation, sécurisé et fonctionnel. Si vous les autorisez également, cliquez sur « Accepter » ou poursuivez simplement votre navigation.

CloseFermer